Background-Dihydropyridine calcium channel blockers protect endothelial cells against ischemia and reperfusion injury, suggesting that nifedipine may increase the in vivo cardiac NO level and thus coronary blood flow (CBF) in ischemic hearts. We tested this hypothesis. Methods and Results-In open-chest dogs, coronary perfusion pressure (CPP) was reduced in the left anterior descending coronary artery so that CBF decreased to one third of the control level, and thereafter CPP was maintained constant (103Ϯ8 to 43Ϯ3 mm Hg, nϭ9). We obtained fractional shortening (FS) and lactate extraction ratio (LER) as indices of regional myocardial contraction and metabolism. Both FS (26.4Ϯ2.1% to 6.7Ϯ2.0%, nϭ9, PϽ0.001) and LER (32Ϯ6% to Ϫ37Ϯ5%, nϭ9, PϽ0.001) showed a decrease when CPP was reduced. After intracoronary infusion of nifedipine (4 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ), CBF increased from 30Ϯ1 to 48Ϯ4 mL ⅐ 100 g Ϫ1 ⅐ min
Background-Dihydropyridine calcium channel blockers protect endothelial cells against ischemia and reperfusion injury, suggesting that nifedipine may increase the in vivo cardiac NO level and thus coronary blood flow (CBF) in ischemic hearts. We tested this hypothesis. Methods and Results-In open-chest dogs, coronary perfusion pressure (CPP) was reduced in the left anterior descending coronary artery so that CBF decreased to one third of the control level, and thereafter CPP was maintained constant (103Ϯ8 to 43Ϯ3 mm Hg, nϭ9). We obtained fractional shortening (FS) and lactate extraction ratio (LER) as indices of regional myocardial contraction and metabolism. Both FS (26.4Ϯ2.1% to 6.7Ϯ2.0%, nϭ9, PϽ0.001) and LER (32Ϯ6% to Ϫ37Ϯ5%, nϭ9, PϽ0.001) showed a decrease when CPP was reduced. After intracoronary infusion of nifedipine (4 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ), CBF increased from 30Ϯ1 to 48Ϯ4 mL ⅐ 100 g Ϫ1 ⅐ min
Ϫ1
(PϽ0.01) without a change of CPP (nϭ9). Both FS (14.0Ϯ1.9%, nϭ9) and LER (Ϫ9Ϯ7%, nϭ9) also increased (PϽ0.01). Nifedipine increased the difference in the level of metabolites of NO (nitrateϩnitrite; 9Ϯ3 to 25Ϯ5 nmol/mL, nϭ9, PϽ0.01) and bradykinin (22Ϯ5 to 58Ϯ4 pmol/mL, nϭ9, PϽ0.01) between coronary venous and arterial blood. L-NAME (an NO synthase inhibitor) or HOE-140 (a bradykinin receptor antagonist) attenuated (PϽ0.05) the increase in CBF (29Ϯ3 and 35Ϯ2 mL ⅐ 100 g Ϫ1 ⅐ min Ϫ1 , nϭ5 each), FS (4.8Ϯ0.6% and 6.9Ϯ1.7%, nϭ5 each), LER (Ϫ47Ϯ8% and Ϫ35Ϯ9%, nϭ5 each), and nitrateϩnitrite (3Ϯ2 and 8Ϯ4 nmol/mL, nϭ5 each) due to nifedipine infusion. Conclusions-These results indicate that the calcium channel blocker nifedipine mediates coronary vasodilation and improves myocardial ischemia through both bradykinin/NO-dependent and -independent mechanisms. (Circulation. 2000;101:311-317.)
Key Words: nitric oxide Ⅲ bradykinin Ⅲ ischemia Ⅲ blood flow C alcium channel blockers are widely used for the treatment of ischemic heart disease because these drugs achieve effective coronary vasodilation. 1 Calcium channel blockers are believed to increase coronary blood flow (CBF) by inhibition of Ca 2ϩ entry into smooth muscle cells. 2 Vascular endothelial function is important for the preservation of organs against ischemic or hypertensive stress, 3 and indeed, nifedipine is reported to be cardioprotective against myocardial ischemia and reperfusion injury. 4 Interestingly, amlodipine increases NO production by unstressed coronary artery endothelial cells via a bradykinin-dependent mechanism, 6 and nifedipine does not have this action. 5 However, because the difference between unstressed and ischemic conditions may influence nifedipineinduced coronary vasodilation and because another dihydropyridine calcium channel blocker (benidipine) increases NO production in ischemic hearts, 6 nifedipine may have the potential to increase cardiac NO levels in ischemic hearts even if it does not increase NO levels in unstressed coronary vessels.
Therefore, we examined whether the calcium channel blocker nifedipine increases CBF via either NO-dependent or -independent mechanisms in ischemic canine hearts. We measured the concentrations of stable degradation products of NO (nitrateϩnitrite) in coronary arterial and venous blood. Furthermore, we examined whether an NO synthase inhibitor or a bradykinin receptor antagonist could attenuate nifedipineinduced coronary vasodilation and the production of NO in ischemic hearts.
Methods

Instrumentation
Mongrel dogs weighing 12 to 23 kg were anesthetized with sodium pentobarbital (30 mg/kg IV). The trachea was intubated, and each dog was ventilated with room air mixed with oxygen. The chest was opened through the left fifth intercostal space, and the heart was suspended in a pericardial cradle. The proximal portion of the left anterior descending coronary artery (LAD) was cannulated and perfused with blood via the left carotid artery through an extracorporeal bypass tube. Coronary perfusion pressure (CPP) was monitored at the tip of the coronary arterial cannula, and CBF in the perfused region was measured with an electromagnetic flow probe attached to the bypass tube. A femoral artery was also cannulated for the sampling of reference (control) blood.
In 39 dogs subjected to protocols I through III, a small, short collecting tube (diameter 1 mm, length 7 cm) was inserted into a small coronary vein near the center of the perfused region to sample coronary venous blood. The drained venous blood was collected in a reservoir placed at the level of the left atrium and was returned via the jugular vein. Left ventricular pressure was measured with a micromanometer (Konigsberg P-5) placed through the apex into the left ventricular cavity. Two pairs of ultrasonic crystals were placed on the inner one third of the myocardium Ϸ1 centimeter apart to measure the myocardial segmental length with an ultrasonic dimension gauge (Schuessler, 5 MHz). End-diastolic length was determined at the R wave of the ECG, and end-systolic length was determined at the minimum dP/dt. 6 We calculated fractional shortening (FS) as an index of myocardial contractility in the perfused region. 6 Nifedipine was obtained from Bayer, and we purchased N Gnitro-L-arginine methyl ester (L-NAME), HOE-140, and bradykinin from Sigma. L-NAME, HOE-140, and bradykinin were dissolved in saline. Nifedipine was dissolved in a mixture of 15% ethanol, 15% polyethylene glycol 400, and 70% distilled water (by volume) and was administered into the coronary artery. The amount of solvent infused was the same in protocols I through IV (0.33 mL/min). In the preliminary study, intracoronary infusion of the solvent for 30 minutes did not change CBF (91Ϯ2 to 97Ϯ4 mL ⅐ 100 g Ϫ1 ⅐ min Ϫ1 , nϭ5), FS (24.4Ϯ2.1% to 26.2Ϯ1.6%, nϭ5), or lactate extraction ratio (LER) (27.2Ϯ3.1% to 23.2Ϯ2.1%, nϭ5).
Experimental Protocols
Protocol 1: Effect of Intracoronary Administration of Nifedipine on Coronary Hemodynamic and Metabolic Parameters in the Nonischemic Myocardium
Five dogs were used in this protocol. Coronary arterial and venous blood were sampled for blood gas analysis and for determination of the levels of NO metabolites (nitrateϩnitrite) and bradykinin. Hemodynamic parameters, ie, left ventricular pressure, dP/dt, and segmental length in the perfused region, were also measured. Four doses (1, 2, 4, and 8 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) of nifedipine were administered into the LAD for 5 minutes each (nϭ5). It took 3 minutes to obtain stable coronary hemodynamic conditions. Between 4 and 5 minutes into each infusion of nifedipine, coronary arterial and venous blood were sampled and systemic and coronary hemodynamic parameters were measured. In the preliminary study (nϭ3), we found that 8 g ⅐ kg Ϫ1 ⅐ min Ϫ1 of nifedipine was the minimum dose that increased CBF by 100% and was the maximum dose that did not cause systemic hemodynamic effects when infused into the coronary artery for 10 minutes. The order of nifedipine doses for intracoronary infusion was randomized. In the same dogs, we also infused the same 4 doses of nifedipine for 5 minutes each after the onset of infusion of L-NAME (10 g ⅐ kg
). In a preliminary study, we confirmed that the dose of either L-NAME or HOE-140 attenuated the coronary vasodilatory action of bradykinin (20 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 IC) by 85Ϯ6% and 89Ϯ7%, respectively (nϭ5). Either L-NAME (nϭ5) or HOE-140 (nϭ5) was administered into the LAD 5 minutes before the administration of nifedipine. We measured the hemodynamic parameters and sampled coronary arterial and venous blood 4 minutes after the onset of infusion of either L-NAME or HOE-140. In 5 dogs, we also examined whether this dose of L-NAME attenuated papaverine (15, 30 , and 60 g ⅐ kg Ϫ1 ⅐ min Ϫ1 IC)-induced coronary vasodilation.
Protocol 2: Effect of Nifedipine on Coronary Hemodynamic and Metabolic Parameters in the Ischemic Myocardium (Constant Low CPP)
Nineteen dogs were used in this protocol. After hemodynamic stabilization, CPP was reduced so that CBF was decreased to 33% of the control CBF with an occluder attached to the extracorporeal bypass tube. After a low level of CPP was obtained, the occluder was adjusted to keep CPP constant. All of the hemodynamic parameters were measured 10 minutes after the onset of hypoperfusion, and both coronary arterial and venous blood were sampled. After these measurements, nifedipine (4 g ⅐ kg Ϫ1 ⅐ min Ϫ1 , nϭ9) was infused into the LAD, and measurement of all hemodynamic and metabolic parameters was repeated after 10 minutes. The dose of 4 g ⅐ kg Ϫ1 ⅐ min Ϫ1 of nifedipine was the maximum dose that caused maximal coronary vasodilation. Thereafter, the infusion of nifedipine was discontinued, and hemodynamic and metabolic parameters were observed at 20 minutes. In other dogs, we infused nifedipine after treatment with either L-NAME (10 g ⅐ kg Ϫ1 ⅐ min Ϫ1 , nϭ5) or HOE-140 (0.5 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 , nϭ5). The time and order of administration of the drugs before the onset of coronary hypoperfusion were the same as in protocol 1. We observed the hemodynamic parameters and sampled coronary arterial and venous blood as in the control group at 4 minutes after the onset of infusion of either L-NAME or HOE-140.
Protocol 3: Effect of Nifedipine on Coronary Hemodynamic and Metabolic Parameters in the Ischemic Myocardium (Constant Low CBF)
Because an increase in CBF may increase shear stress in the coronary arteries, which may secondarily increase the cardiac NO level in ischemic hearts, we tested the effect of nifedipine on cardiac NO levels under constant low CPP. In 15 dogs, after hemodynamic stabilization, CPP was reduced so that CBF was decreased to 33% of the control CBF with an occluder attached to the extracorporeal bypass tube. After a low level of CBF was obtained, the occluder was adjusted to keep CBF constant. All of the hemodynamic parameters were measured 10 minutes after the onset of hypoperfusion, and both coronary arterial and venous blood were sampled. After these measurements, nifedipine (4 g ⅐ kg Ϫ1 ⅐ min Ϫ1 , nϭ5) was infused into the LAD, and measurements of all hemodynamic and metabolic parameters were repeated after 10 minutes. Thereafter, the infusion of nifedipine was discontinued, and hemodynamic and metabolic parameters were observed at 20 minutes. In other dogs, we infused nifedipine after treatment with either L-NAME (10 g ⅐ kg Ϫ1 ⅐ min Ϫ1 , nϭ5) or HOE-140 (0.5 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 , nϭ5). The time and order of administration of the drugs before the onset of coronary hypoperfusion were the same as in protocol 2.
Protocol 4: Effect of Nifedipine on the cGMP Content of Epicardial Coronary Arteries in Ischemic Hearts
In 20 dogs, we investigated whether nifedipine increased the cGMP content of the epicardial arteries in the ischemic myocardium. With an occluder attached to the extracorporeal bypass tube, CPP was reduced so that CBF decreased to one third of the control CBF. After a low CPP was established, the occluder was adjusted to keep CPP at a constant low level. After this low CPP was maintained for 10 minutes, we infused either nifedipine (4 g ⅐ kg Ϫ1 ⅐ min
Ϫ1
, nϭ10) or the solvent (nϭ10) into the LAD for 10 minutes with and without L-NAME. Next, we rapidly removed the epicardial LAD (ischemic region) and left circumflex coronary artery (nonischemic control region) using precooled scissors and a pair of large tweezers and stored the sampled vessels in liquid nitrogen.
Biochemical Analysis
Lactate concentration was assessed by an enzymatic assay. 7 LER was calculated by multiplying the coronary arteriovenous difference in the lactate concentration by 100 and dividing it by the arterial lactate concentration.
The methods for NO 8 and bradykinin 9 measurement have been described previously. For these measurements, 2 mL of blood was sampled.
The method of tissue cGMP measurement has been described previously. 10 
Statistical Analysis
Statistical analysis was performed among the groups by ANOVA. 11, 12 When ANOVA revealed a significant difference, Bonferroni's correction was applied. 12 All values were expressed as meanϮSEM. A value of PϽ0.05 was considered significant.
Results
Effect of Intracoronary Administration of Nifedipine on Coronary Hemodynamic and Metabolic Parameters in the Nonischemic Myocardium (Protocol 1)
The baseline systolic and diastolic blood pressure, heart rate, and CPP were 138Ϯ5 (nϭ5) and 84Ϯ6 (nϭ5) mm Hg, 136Ϯ6 bpm (nϭ5), and 105Ϯ6 mm Hg (nϭ5), respectively, and the intracoronary administration of either L-NAME, HOE-140, or nifedipine did not significantly change any of these parameters. In the untreated condition, nifedipine increased the nitrateϩnitrite level in the coronary venous blood relative to that in arterial blood [⌬VA(NO)], as shown in Figure 1 . Nifedipine also increased the bradykinin level in the coronary venous blood relative to that in arterial blood [⌬VA(bradykinin): 1.2Ϯ1.8 pmol/mL at baseline to 3.4Ϯ1.5, 12Ϯ2 (PϽ0.01), 23Ϯ4 (PϽ0.05), and 27Ϯ2 (PϽ0.01) pmol/mL with 1, 2, 4, and 8 g ⅐ kg Ϫ1 ⅐ min Ϫ1 of nifedipine, respectively (nϭ5 each)]. Nifedipine increased CBF dosedependently ( Figure 2 ). This increase in CBF was partially attenuated by either L-NAME or HOE-140. Papaverine increased CBF, and this increase was not attenuated by L-NAME [92Ϯ2 and 89Ϯ2 mL ⅐ 100 g Ϫ1 ⅐ min Ϫ1 at baseline with and without L-NAME (nϭ5 each); 130Ϯ6 and 126Ϯ6 mL ⅐ 100 g Ϫ1 ⅐ min
Ϫ1
, 163Ϯ7 and 159Ϯ8 mL ⅐ 100 g Ϫ1 ⅐ min
, and 198Ϯ6 and 205Ϯ9 mL ⅐ 100 g Ϫ1 ⅐ min Ϫ1 at 15, 30, and 60 g ⅐ kg Ϫ1 ⅐ min Ϫ1 of papaverine with and without L-NAME (nϭ5 each)].
Effect of Nifedipine on Coronary Hemodynamic and Metabolic Parameters in the Ischemic Myocardium (Constant Low CPP) (Protocol 2)
The baseline systolic and diastolic blood pressure and heart rate were 142Ϯ4 (nϭ19) and 82Ϯ4 (nϭ19) mm Hg and 136Ϯ4 bpm, respectively (nϭ19) in the control state. Neither the intracoronary administration of L-NAME, HOE-140, or nifedipine nor the reduction of CPP significantly changed these parameters. In the low-constant-CPP protocol, 10 minutes after the reduction in CPP, ⌬VA(NO) (Figure 3 ) and ⌬VA(bradykinin) (2.0Ϯ3.3 at baseline to 22Ϯ5 pmol/mL, PϽ0.05, nϭ9 each) were increased, and nifedipine further increased ⌬VA(NO) (Figure 3 ) and ⌬VA(bradykinin) (58Ϯ4 pmol/mL, PϽ0.01, nϭ9 each). In accordance with the in- crease in ⌬VA(NO), nifedipine increased CBF despite the constant CPP (Figure 4 ). FS and LER, which were reduced after the onset of coronary hypoperfusion, were increased by nifedipine administration ( Figure 5 ). These beneficial effects of nifedipine on the ischemic heart were attenuated by either L-NAME or HOE-140.
Effect of Nifedipine on Coronary Hemodynamic and Metabolic Parameters in the Ischemic Myocardium (Constant Low CBF) (Protocol 3)
The baseline systolic and diastolic blood pressure and heart rate were 140Ϯ3 (nϭ15) and 86Ϯ2 (nϭ15) mm Hg and 141Ϯ2 bpm (nϭ15), respectively, in the control state. Neither the intracoronary administration of L-NAME, HOE-140, or nifedipine nor the reduction of CPP significantly changed these parameters. In the ischemic hearts with a low constant CBF, ⌬VA(bradykinin) (2.0Ϯ3.0 pmol/mL at baseline to 28Ϯ5 pmol/ mL, PϽ0.05, nϭ5 each) was increased, and nifedipine further increased ⌬VA(bradykinin) (56Ϯ7 pmol/mL, PϽ0.05, nϭ5 each). Nifedipine also increased ⌬VA(NO), which was attenuated by L-NAME (Figure 6 ). Nifedipine decreased CPP because of coronary vasodilation, and this change was attenuated by either L-NAME or HOE-140 (Figure 7) . Because CBF remained constant, neither FS nor LER was altered (Figure 8 ).
Effect of Nifedipine on the cGMP Content of Epicardial Coronary Arteries in Ischemic Hearts (Protocol 4)
Because NO increases cellular cGMP levels, we measured cGMP levels in the epicardial coronary artery with and without nifedipine. Without L-NAME (CPP 105Ϯ3 to 47Ϯ3 mm Hg, CBF 89Ϯ2 to 30Ϯ2 mL ⅐ 100 g Ϫ1 ⅐ min
Ϫ1
, nϭ5 each), nifedipine increased the cGMP content of the epicardial coronary arteries (247Ϯ13 versus 156Ϯ15 fmol/mg wet wt (PϽ0.05) with and without nifedipine in the ischemic region, nϭ5 each), and this effect was blunted by treatment with L-NAME (49Ϯ8 versus 56Ϯ9 fmol/mg wet wt, PϭNS, with and without nifedipine in the ischemic region, nϭ5 each).
Discussion
We showed here that nifedipine increases CBF via a bradykinin/NO-dependent mechanism in addition to the bradykinin/NO-independent relaxation of coronary resistance vessels via the blockade of calcium channels, both of which contribute to coronary vasodilation and attenuate the severity of myocardial ischemia.
Nifedipine-Induced NO Production and Coronary Vasodilation in Nonischemic or Ischemic Hearts
It is reported that amlodipine increases NO production by canine coronary endothelial cells but that nifedipine does with infusion and withdrawal of nifedipine during coronary hypoperfusion. Although reduced CPP was maintained at a constant level, nifedipine increased CBF, with this effect being blunted by either L-NAME (10 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) or HOE-140 (0.5 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ). Statistical analysis was performed by ANOVA followed by Bonferroni's correction.
not. 5 This result may seem to be contradictory to our findings, although it is not. First, Zhang and Hintze 5 observed NO production only by coronary arterial endothelial cells. NO is produced not only by endothelial cells 13 but also by cardiac myocytes, 14 erythrocytes, 15 platelets, 16 leukocytes, 17 and fibroblasts 18 in the heart. Therefore, it may be possible that nifedipine stimulates NO release from cells other than endothelial cells. Second, because nifedipine increases NO levels in the ischemic myocardium more than in the nonischemic myocardium, as revealed in the present study, nifedipine may have a less potent effect on NO production than amlodipine in the unstressed nonischemic myocardium.
In nonischemic hearts, because L-NAME partially inhibited nifedipine-induced coronary vasodilation in the present study, the contribution of NO/bradykinin to nifedipine-induced coronary vasodilation seemed to be Ϸ30% (Figure 2 ). The remainder of nifedipine-induced coronary vasodilation is attributable to the inhibition of Ca 2ϩ entry into coronary smooth muscle. In contrast, nifedipineinduced coronary vasodilation was largely attenuated by L-NAME in ischemic hearts, suggesting that the effect of nifedipine on the ischemic myocardium was more attributable to NO than its effect on the nonischemic myocardium.
Mechanisms of the Nifedipine-Induced Increase in NO Levels
Because calcium channel blockers increase CBF via inhibition of Ca 2ϩ entry into smooth muscle cells 2 and the increase in shear stress due to an increase in CBF enhances NO production by endothelial cells, one may argue that the increase in NO levels due to nifedipine is secondary to the increase in shear stress after the increase in CBF. In the present study, however, L-NAME did not attenuate papaverine-induced coronary vasodilation, and even when CBF was kept constant at a low level during infusion of nifedipine, the cardiac NO level was increased. These results indicate that nifedipine directly affected the metabolism of NO.
Several stimuli exist that facilitate NO production. Acetylcholine, bradykinin, purines, and norepinephrine can all stimulate NO synthase. 13 The receptors for one of these substances may already be stimulated because of ischemic stress, and nifedipine may increase the cardiac levels of one of these substances to stimulate the receptor. A calcium channel blocker is reported to activate kallikrein in the kidney, 19 which may enhance the increase in bradykinin production in the ischemic heart. Indeed, we showed that nifedipine increases cardiac bradykinin levels, but in the present study we did not elucidate the cellular mechanisms by which nifedipine raises cardiac bradykinin levels.
Physiological and Clinical Relevance
Interestingly, the coronary hemodynamic and metabolic parameters did not completely return to the baseline level by 20 minutes after the withdrawal of nifedipine infusion during coronary hypoperfusion. We observed these parameters for Nifedipine increased cardiac NO levels, with this change being blunted by either L-NAME (10 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) or HOE-140 (0.5 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ). Statistical analysis was performed by ANOVA followed by Bonferroni's correction. 40 minutes after the discontinuation of nifedipine in the ischemic hearts of other dogs, and we observed only a slight decrease in CBF, but the parameters did not return to baseline, although nifedipine was not detected in the coronary venous blood (data not shown). Nifedipine may bind to the calcium channels or may directly or indirectly affect NO synthase for several hours to cause coronary vasodilation.
NO is believed to attenuate the severity of myocardial ischemia; NO increases CBF, 3 decreases myocardial anaerobic metabolism, 20 inhibits platelet aggregation 14 and leukocyte activation, 20 and attenuates sympathetic nerve activity 21 in ischemic hearts. Furthermore, NO is reported to mediate cardioprotection in the late phase of ischemic preconditioning, because at 24 or 48 hours after a brief period of ischemia, NO has an infarct size-limiting effect, 22 which is blunted by L-NAME. The present results suggest that nifedipine may be beneficial for ischemic heart disease. However, nifedipine has not been found to be useful for myocardial salvage or reduction of myocardial ischemia in patients with acute myocardial infarction and patients with unstable angina. Indeed, in the presence of collateral vessels, nifedipine may cause the myocardial steal phenomenon and lead to worsening of ischemia in patients with ischemic heart disease. Therefore, we should be careful in extrapolating the present results to the clinical settings unless a large-scale clinical trial proves the utility of nifedipine. 
